VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail mail@viartis.net.

                                           

 

30th  September 2017 - New research

ALPHA-SYNUCLEIN PREDICTS THE COGNITIVE DECLINE IN PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

It is often claimed that alpha-synculein is a hallmark of Parkinson's Disease or indicates its severity. It has even been wrongly claimed to be the primary cause of Parkinson's Disease. However, it has instead been found to be related to the cognitive decline that can occur in Parkinson's Disease, especially as Parkinson's Disease worsens.

Plasma levels of alpha-synuclein were much higher in people with  Parkinson's Disease. However, although there was a significant increase in plasma alpha-synuclein levels in people with Parkinson's Disease, in later stages of Parkinson's Disease there was no correlation with motor symptom severity, as assessed by Unified Parkinson's Disease Rating Scale part III scores (the main Parkinson's Disease symptom score). However, plasma alpha-synuclein levels were significantly higher in people with Parkinson's Disease who had dementia than in people with Parkinson's Disease who only had mild cognitive impairment or normal cognition.

The results suggest that plasma alpha-synuclein level correlates with cognitive decline but not with motor severity in people with Parkinson's Disease. Plasma alpha-synuclein could therefore serve as a biomarker for people with Parkinson's Disead at risk of cognitive decline.

Reference : Journal of Neurology, Neurosurgery and Psychiatry [2017] 88 (10) : 818-824 (C.H.Lin, S.Y.Yang, H.E.Horng, C.C.Yang, J.J.Chieh, H.H.Chen, B.H.Liu, M.J.Chiu) Complete abstract   For more news go to Parkinson's Disease News

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail mail@viartis.net with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.


 

THE COMPREHENSIVE GUIDE TO PARKINSON'S DISEASE

The Comprehensive Guide to Parkinson's Disease, which is fully referenced, and over 800 pages long, is the most comprehensive book concerning Parkinson's Disease. It includes the history of Parkinson 's Disease, famous people with Parkinson's Disease, the complete biochemisty of Parkinson's Disease,
its cytology and cytological effects, anatomy and anatomical effects, physiology and physiological effects, symptoms of every system in the body, the diagnosis methods (observational, technological, chemical), biochemical causes, all the toxic causes, all the genetic causes, all the pharmacological causes, all the medical disorders that cause Parkinson's Disease symptoms, its treatments (biochemical, pharmacological, surgical, natural, exercise methods, technological methods), including all those treatments that exist and all those treatments presently being developed, Parkinson's Disease organisations, Parkinson's Disease web sites, and books on Parkinson's Disease nursing. CLICK HERE FOR MORE DETAILS

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
2006-2017  Viartis
 
2017-09-30 17:28:41
 
MAIL@VIARTIS.NET